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ABSTRACT 
Melanotransferrin or melanoma tumour antigen p97 (MTf) is a transferrin homologue 
that is found predominantly bound to the cell membrane via a glycosyl 
phosphatidylinositol anchor. The molecule is a member of the transferrin super-family 
that binds iron through a single high affinity iron(III)-binding site. Melanotransferrin 
was originally identified at high levels in melanoma cells and other tumours, but at 
lower levels in normal tissues. Since its discovery, the function of MTf has remained 
intriguing, particularly regarding its role in cancer cell iron transport. In fact, 
considering the crucial role of iron in many metabolic pathways e.g., DNA and haem 
synthesis, it is important to understand the function of melanotransferrin in the transport 
of this vital nutrient. Melanotransferrin has also been implicated in diverse 
physiological processes, such as plasminogen activation, angiogenesis, cell migration 
and eosinophil differentiation. Despite these previous findings, the exact biological and 
molecular function(s) of MTf remain elusive. Therefore, it was important to investigate 
the function of this molecule in order to clarify its role in biology.  
 
To define the roles of MTf, six models were developed during this investigation. These 
included: the first MTf knockout (MTf -/-) mouse; down-regulation of MTf expression 
by post-transcriptional gene silencing (PTGS) in SK-Mel-28 and SK-Mel-2 melanoma 
cells; hyper-expression of MTf expression in SK-N-MC neuroepithelioma cells and 
LMTK- fibroblasts cells; and a MTf transgenic mouse (MTf Tg) with MTf hyper-
expression. 
 
  
xiv 
The MTf -/- mouse was generated through targeted disruption of the MTf gene. These 
animals were viable, fertile and developed normally, with no morphological or 
histological abnormalities. Assessment of Fe indices, tissue Fe levels, haematology and 
serum chemistry parameters demonstrated no differences between MTf -/- and wild-type 
(MTf +/+) littermates, suggesting MTf was not essential for Fe metabolism. However, 
microarray analysis showed differential expression of molecules involved in 
proliferation such as myocyte enhancer factor 2a (Mef2a), transcription factor 4 (Tcf4), 
glutaminase (Gls) and apolipoprotein d (Apod) in MTf -/- mice compared with MTf +/+ 
littermates. 
 
Considering the role of MTf in melanoma cells, PTGS was used to down-regulate MTf 
mRNA and protein levels by >90% and >80%, respectively. This resulted in inhibition 
of cellular proliferation and migration. As found in MTf -/- mice, melanoma cells with 
suppressed MTf expression demonstrated up-regulation of MEF2A and TCF4 in 
comparison with parental cells. Furthermore, injection of melanoma cells with 
decreased MTf expression into nude mice resulted in a marked reduction of tumour 
initiation and growth. This strongly suggested a role for MTf in proliferation and 
tumourigenesis.  
 
To further understand the function of MTf, a whole-genome microarray analysis was 
utilised to examine the gene expression profile of five models of modulated MTf 
expression. These included two stably transfected MTf hyper-expression models (i.e., 
SK-N-MC neuroepithelioma and LMTK- fibroblasts) and one cell type with down-
regulated MTf expression (i.e., SK-Mel-28 melanoma). These findings were then 
  
xv 
compared with alterations in gene expression identified using the MTf -/- mouse. In 
addition, the changes identified from the microarray data were also assessed in another 
model of MTf down-regulation in SK-Mel-2 melanoma cells. In the cell line models, 
MTf hyper-expression led to increased proliferation, while MTf down-regulation 
resulted in decreased proliferation. Across all five models of MTf down- and up-
regulation, three genes were identified as commonly modulated by MTf. These included 
ATP-binding cassette sub-family B member 5 (Abcb5), whose change in expression 
mirrored MTf down- or up-regulation. In addition, thiamine triphosphatase (Thtpa) and 
Tcf4 were inversely expressed relative to MTf levels across all five models. The 
products of these three genes are involved in membrane transport, thiamine 
phosphorylation and proliferation/survival, respectively. Hence, this study identifies 
novel molecular targets directly or indirectly regulated by MTf and the potential 
pathways involved in its function, including modulation of proliferation.  
 
To further understand the function of MTf, transgenic mice bearing the MTf gene under 
the control of the human ubiquitin-c promoter were generated and characterised. In 
MTf Tg mice, MTf mRNA and protein levels were hyper-expressed in a variety of tissues 
compared with control mice. Similar to the MTf -/- mice, these animals exhibited no 
gross morphological, histological, nor Fe status changes when compared with wild-type 
littermates. The MTf Tg mice were also born in accordance with classical Mendelian 
ratios. However, haematological data suggested that hyper-expression of MTf leads to a 
mild, but significant decrease in erythrocyte count.  
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In conclusion, the investigations described within this thesis clearly demonstrate no 
essential role for MTf in Fe metabolism both in vitro and in vivo. In addition, this study 
generates novel in vitro and in vivo models for further investigating MTf function. 
Significantly, the work presented has identified novel role(s) for MTf in cell 
proliferation, migration and melanoma tumourigenesis. 
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